Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials

Thrombosis and Haemostasis

Volumn 98, Issue 4, 2007, Pages 852-857

  Iijima, Raisuke ^a   Ndrepepa, Gjin ^a   Mehilli, Julinda ^a   Bruskina, Olga ^a   Schulz, Stefanie ^b   Schömig, Albert ^a,b   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Abciximab; Clopidogrel; Percutaneous coronary intervention; Platelet count

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; INSULIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ANGIOGRAPHY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; DIABETES COMPLICATIONS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET COUNT; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 35048886977     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-04-0285     Document Type: Article

References (34)

1. Thaulow E, et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
2. Schuhlen H, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998; 98: 104-111.
3. Schuhlen H, et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 2001; 37: 2066-2073.
4. Joner M, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
5. Schömig A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.
6. Kastrati A, et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 1997; 96: 462-467.
7. Schömig A, et al, Coronary stenting plus platelet glycoprotein IIb/ IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000; 343: 385-391.
8. Schömig A, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 2005; 26: 1379-1384.
9. Wong CK, et al. Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction. Am J Cardiol 2002; 90: 54-57.
10. Turakhia MP, et al. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol 2004; 94: 1406-1410.
11. Ly HQ, et al. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol 2006; 98: 1-5.
12. Nikolsky E, et al. Impact of Baseline Platelet Count in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the CADILLAC Trial). Am J Cardiol 2007; in press.
13. Yusuf S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
14. Mehra SR, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
15. Steinhubl SR, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
16. Muller I, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
17. Kastrati A, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-238.
18. Hausleiter J, et al. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med 2004; 256: 388-397.
19. Mehilli J, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627-3635.
20. Kastrati A, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. J Am Med Assoc 2006; 295: 1531-1538.
21. TIMI Study Group. Definitions used in TIMI trials. Available at: http://www.timi.org. accessed March 29, 2007.
22. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101: 570-580.
23. Cannon CP, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-1887.
24. de Winter RJ, et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J 2002; 23: 960-966.
25. Dibra A, et al. Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. Eur Heart J 2003; 24: 1128-1133.
26. Prasad A, et al. Relation Between Leucocyte Count, Myonecrosis, Myocardial Perfusion, and Outcomes Following Primary Angioplasty. Am J Cardiol 2007; in press.
27. Heeschen C, t al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
28. Aukrust P, et al. Inflammatory role of platelets in acute coronary syndromes. Heart 2001; 86: 605-606.
29. George JN. Platelets. Lancet 2000; 355: 1531-1539.
30. Barron HV, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy Circulation 2000; 102: 2329-2334.
31. Gibson CM, et al. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol 2006; 98: 761-763.
32. Campo G, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48: 2178-2185.
33. Hochholzer W, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
34. Huczek Z, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 46: 284-290.